NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.57 -0.82 (-6.62 %)
(As of 06/25/2018 02:28 AM ET)
Previous Close$11.57
Today's Range$11.46 - $12.50
52-Week Range$5.42 - $20.73
Volume1.69 million shs
Average Volume226,248 shs
Market Capitalization$168.02 million
P/E Ratio-4.67
Dividend YieldN/A
Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio6.51
Quick Ratio6.51


Trailing P/E Ratio-4.67
Forward P/E Ratio-3.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales15,688.92
Cash FlowN/A
Price / CashN/A
Book Value$4.50 per share
Price / Book2.57


EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-59.98%
Return on Assets-52.73%


Outstanding Shares13,560,000

The Truth About Cryptocurrencies

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.91) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.23. View Zynerba Pharmaceuticals' Earnings History.

What price target have analysts set for ZYNE?

11 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $18.45 in the next year. View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 60)
  • Ms. Terri B. Sebree, Pres (Age 60)
  • Mr. James E. Fickenscher, CFO & VP of Corp. Devel. (Age 54)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
  • Ms. Suzanne M. Hanlon, Sec., VP of HR & Gen. Counsel (Age 61)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

News stories about ZYNE stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media headlines about the company an impact score of 47.45 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.27%), Northern Trust Corp (1.23%), Millennium Management LLC (0.77%), A.R.T. Advisors LLC (0.64%), Wells Fargo & Company MN (0.31%) and Alps Advisors Inc. (0.27%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Northern Trust Corp, A.R.T. Advisors LLC, Alps Advisors Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $11.57.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $168.02 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  286 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.